$0.59-10.0%Nov 13 close
Reported results on November 5, 2026; they are not in these figures yet.
Next earnings: November 19, 2026
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
Aptevo Therapeutics Inc. is scheduled to report next on November 19, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toDec 31, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $3.7M | -100.00% |
| Free Cash Flow | -$5.9M | -$5.4M | -9.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Aptevo Therapeutics Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“During the second quarter, we made important progress against the programs and initiatives we believe can create near- and long-term value for Aptevo,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company developing novel multispecific immunotherapies for the treatment of cancer. The Company’s lead clinical candidate, mipletamig, is currently being evaluated in frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Aptevo’s pipeline is generated from its proprietary ADAPTIR and ADAPTIR-FLEX platforms and includes bispecific and trispecific candidates designed to create multiple oncology value drivers across hematologic malignancies and solid tumors. In preclinical development, Aptevo is advancing APVO451, a nectin-4-targeted trispecific immunotherapy candidate for solid tumors and is pursuing strategic opportunities in radiopharmaceutical therapeutics to extend its tumor-targeting expertise into additional cancer treatment approaches.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aptevo Therapeutics Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.